Home › Products › Oncology › Gazyva 1000mg Injection
Gazyva 1000mg Injection
Salt Composition: OBINUTUZUMAB
- Manufacturer: ROCHE PRODUCTS INDIA PVT LTD
- Pack Size: 1 VIAL(s) OF 40ML
- Dosage Form: INJECTION
- Strength: 1000MG
- Prescription Required
- Cold Chain
- Prepaid Only. Non-Returnable.
- Storage: Store Gazyva 1000mg injection in the refrigerator (2°C to 8°C) Do not freeze keep the injection away from the reach of children and pets. If you have missed any dosing appointments, inform your doctor and schedule immediately.
₹285218.00₹356522.32
Inclusive of all taxes
Product Introduction
Gazyva 1000mg injection contains the active substance obinutuzumab. It is an antineoplastic drug that belongs to the class of medications called anti-CD20 monoclonal antibodies. It is used in combination with other anticancer medicines to treat chronic lymphocytic leukaemia (CLL) and non-Hodgkin's lymphoma (NHL) in adults. It works by killing cancer cells and stopping them from growing.
Do not take this Gazyva 1000mg injection if you are allergic to obinutuzumab or any other ingredients of this medicine.
Inform your physician if you have an active infection, or have suffered from any infections, a weak immune system, have or have had heart problems, brain disorders, eye disorders, breathing problems, or liver diseases.
Report to your physician if you experience any symptoms of sudden difficulty in breathing, dizziness, diarrhoea, cough, skin rash, chest pain, or fever after administration of the injection.
Inform your physician if you experience any symptoms of memory loss, trouble speaking, difficulty walking, or problems with your eyesight during treatment with Gazyva 1000mg injection, as these may indicate rare and life-threatening side effects.
This medicine is not recommended for children and young people under 18 years of age.
Use an effective method of contraception while being treated with this injection. Avoid pregnancy and breastfeeding during treatment.
Uses
Chronic lymphocytic leukemia (CLL) Non-Hodgkinâs lymphoma (NHL)
How it works
Chronic lymphocytic leukemia (CLL) and Non-Hodgkinâs lymphoma (NHL) are types of cancer that affect a specific type of WBC called B-lymphocytes. The affected cells multiply too quickly and survive longer. Gazyva 1000mg injection binds to CD20 targets on the surface of the affected B-lymphocyte cells and causes them to die. When the injection is administered to the patient with other anticancer medicines, this slows down the progression time of the disease and works effectively by killing the abnormal cancer cells.
How to Use
It will be given to you by a doctor or nurse in a hospital or clinic setting trained in cancer chemotherapy. It is given as an intravenous infusion drip (into your vein) for several hours. Do not self-administer the injection. Your doctor will decide the dose and duration of the treatment based on your disease severity, body weight, and other factors. Your doctor will give you certain medications to lessen the chance of getting side effects from the Gazyva 1000mg injection treatment.
Side Effects
Side effects are unwanted symptoms caused by medicines. Even though all drugs cause side effects, not everyone gets them. Common Hair fall Constipation, diarrhea Anemia Decreased WBC and platelets Infection Muscle pain Headache, insomnia Urinary tract infections Cough Fever, tiredness Decreased appetite Serious Bleeding in the stomach Anemia Hypersensitivity reactions Brain problems Severe infections
Expert Tips
Gazyva 1000mg injection may interfere with vaccines, inform your physician before taking any flu shot or any other vaccines. This injection may cause severe birth defects if taken during pregnancy. Female patients with reproductive potential should use effective contraception during the treatment. Do not breastfeed during treatment and for 6 months after your last dose. Inform your doctor if you have a history of hepatitis B infection. This medicine may make you bleed, bruise, or get infections more easily. Take precautions to prevent illness and injury. Wash your hands often. Your doctor may advise you to take certain tests to check for the effectiveness of the therapy.
References
- Gazyvaro 1,000 mg concentrate for solution for infusion - Patient Information Leaflet (PIL) - (emc). www.medicines.org.uk. [Revised 2022] [cited 2023 Apr 25]. Available from: https://www.medicines.org.uk/emc/product/3279/pil
- GAZYVA-obinutuzumab injection. [revised on 2017] [cited 2023 Apr 25]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/125486s017s018lbl.pdf
- Jenny OâNions, William Townsend et al; The role of obinutuzumab in the management of follicular lymphoma; Future Oncology; Published on Nov 2019; Accessed on 25/04/2023; https://pubmed.ncbi.nlm.nih.gov/31538821/
Safety Advice
Pregnancy: unsafe Gazyva 1000mg injection is unsafe to administer in pregnant women because it may affect the fetus. Inform your physician if you are pregnant, suspect pregnancy, or planning to become pregnant. Using an effective birth control method during the treatment and for 18 months after your last dose is necessary.
Lungs: Consult your doctor It is unknown whether Gazyva 1000mg injection can be used in patients with lung disorders. Consult your doctor if you have any lung diseases before starting the treatment.
Breastfeeding: unsafe Breastfeeding is not recommended in patients taking Gazyva 1000mg injection because the medicine passes into the breast milk in small amounts and may harm your baby.
Disclaimer
The information provided on this page is intended for general informational purposes only and should not be considered as medical advice. Always consult a qualified healthcare professional before starting, stopping, or changing any medication. Self-medication can be harmful. Med For Rare does not endorse self-diagnosis or self-treatment.